Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighte...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnet, Megan B., Cooper, Wendy A., Boyer, Michael J., Kao, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024943/
https://www.ncbi.nlm.nih.gov/pubmed/29904031
http://dx.doi.org/10.3390/jcm7060151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024943/
https://www.ncbi.nlm.nih.gov/pubmed/29904031
http://dx.doi.org/10.3390/jcm7060151

Ejemplares similares